In vitro evaluation of avidin antibody pretargeting using 211at-labeled and biotinylated poly-L-lysine as effector molecule

Cancer

Volumn 116, Issue SUPPL. 4, 2010, Pages 1101-1110

  Frost, Sofia H L ^a   Jensen, Holger ^b   Lindegren, Sture ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b University of Copenhagen   (Denmark)

Author keywords

Astatine 211; Avidin; Biotin; Polylysine; Pretargeted radioimmunotherapy

Indexed keywords

4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLIC ACID 3 SULFO N HYDROXYSUCCINIMIDE ESTER SODIUM SALT; ASTATINE 211; AVIDIN; BIOTIN; BIOTIN DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; DODECYL SULFATE SODIUM; IMINOBIOTIN; MONOCLONAL ANTIBODY; MONOMER; POLYLYSINE; SUCCINIC ANHYDRIDE; SUCCINIMIDE DERIVATIVE; SUCCINIMIDYL 6 (BIOTINAMIDO)HEXANOIC ACID; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BIOTINYLATION; CHEMICAL MODIFICATION; CLINICAL EVALUATION; COLUMN CHROMATOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG TARGETING; EFFECTOR CELL; FAST PROTEIN LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MOLECULE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; PURIFICATION; RADIOASSAY; RADIOIMMUNOTHERAPY; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; AVIDIN; BIOTINYLATION; MICE; MICE, NUDE; PEPTIDES; RADIOIMMUNOTHERAPY;

EID: 76249107452     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24798     Document Type: Conference Paper

References (37)

1. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802-1807.
2. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
3. Sung C, van Osdol WW. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl Med. 1995;36:867-876.
4. Subbiah K, Hamlin DK, Pagel JM, et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med. 2003;44:437-445.
5. Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 1991;51:6650-6655.
6. Sakahara H, Saga T. Avidin-biotin system for delivery of diagnostic agents. Adv Drug Deliv Rev. 1999;37(1-3):89-101.
7. Rusckowski M, Qu T, Chang F, Hnatowich DJ. Pretargeting using peptide nucleic acid. Cancer. 1997;80(suppl 12):2699-2705.
8. Kuijpers WH, Bos ES, Kaspersen FM, Veeneman GH, van Boeckel CA. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for 2-step radioimmunotherapy of cancer. Bioconjug Chem. 1993;4:94-102.
9. Foulon CF, Bigner DD, Zalutsky MR. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. Bioconjug Chem. 1999;10:867-876.
10. Hylarides MD, Mallett RW, Meyer DL. A robust method for the preparation and purification of antibody/streptavidin conjugates. Bioconjug Chem. 2001;12:421-427.
11. Jia F, Shelton TD, Lewis MR. Preparation, characterization, and biological evaluation of a streptavidin-chimeric t84.66 conjugate for antibody pretargeting. Cancer Biother Radiopharm. 2007;22:654-664.
12. Schultz J, Lin Y, Sanderson J, et al. A tetravalent singlechain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 2000;60:6663-6669.
13. Laitinen OH, Airenne KJ, Raty JK, Wirth T, Yla-Herttuala SY. Avidin fusion protein strategies in targeted drug and gene delivery. Letters in Drug Design & Discovery. 2005;2:124-132.
14. del Rosario RB, Wahl RL. Biotinylated iodo-polylysine for pretargeted radiation delivery. J Nucl Med. 1993;34:1147-1151.
15. Torchilin VP. Biotin-conjugated polychelating agent. Bioconjug Chem. 1999;10:146-149.
16. Lindegren S, Andersson H, Jacobsson L, Back T, Skarnemark G, Karlsson B. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy. Bioconjug Chem. 2002;13:502-509.
17. Lindegren S, Karlsson B, Jacobsson L, Andersson H, Hultborn R, Skarnemark G. At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L- and poly-D-Lysine as multicarriers. Clin Cancer Res. 2003;9(10, pt 2):3873S-3879S.
18. Pagel JM, Hedin N, Subbiah K, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood. 2003;101:2340-2348.
19. Cremonesi M, Ferrari M, Chinol M, et al. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med. 1999;26:110-120.
20. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-1711.
21. Gautherot E, Rouvier E, Daniel L, et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J Nucl Med. 2000;41:480-487.
22. Urbano N, Papi S, Ginanneschi M, et al. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT). Eur J Nucl Med Mol Imaging. 2007;34:68-77.
23. Lewis MR, Zhang J, Jia F, et al. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol. 2004;31:213-223.
24. Kassis AI. Therapeutic radionuclides: biophysical and radio-biologic principles. Semin Nucl Med. 2008;38:358-366.
25. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25:1341-1351.
26. Lindegren S, Back T, Jensen HJ. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 2001;55:157-160.
27. Lindegren S, Frost S, Back T, Haglund E, Elgqvist J, Jensen H. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate. J Nucl Med. 2008;49:1537-1545.
28. Hamblett KJ, Kegley BB, Hamlin DK, et al. A streptavidinbiotin binding system that minimizes blocking by endogenous biotin. Bioconjug Chem. 2002;13:588-598.
29. Liu G, Mang'era K, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. J Nucl Med. 2002;43:384-391.
30. Rusckowski M, Fogarasi M, Fritz B, Hnatowich DJ. Effect of endogenous biotin on the applications of streptavidin and biotin in mice. Nucl Med Biol. 1997;24:263-268.
31. Sharkey RM, Karacay H, Griffiths GL, et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjug Chem. 1997;8:595-604.
32. Foulon CF, Alston KL, Zalutsky MR. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. Nucl Med Biol. 1998;25:81-88.
33. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res. 2005;11(19, pt 2):7109s-7121s.
34. Martensson L, Nilsson R, Ohlsson T, Sjogren HO, Strand SE, Tennvall J. Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a 2-step pretargeting strategy. Clin Cancer Res. 2007;13(18, pt 2):5572s-5576s.
35. Chen JQ, Strand SE, Tennvall J, Lindgren L, Hindorf C, Sjogren HO. Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96. J Nucl Med. 1997;38:1934-1939.
36. Norrgren K, Strand SE, Nilsson R, Lindgren L, Sjogren HO. A general, extracorporeal immunoadsorption method to increase the tumor-to-normal tissue ratio in radioimmunoimaging and radioimmunotherapy. J Nucl Med. 1993;34:448-454.
37. Foulon CF, Schoultz BW, Zalutsky MR. Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide. Nucl Med Biol. 1997;24:135-143.